Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.64 |
| ▸ | MAPT | P10636 | 10/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928687 | 0.88 | DCTPP1 (0.66) | DCTPP1LMNANPSR1ALDH1A1MAPT | |
| SCHEMBL12684718 | 0.83 | ALDH1A1 (0.82) | LMNANPSR1ALDH1A1MAPTMEN1 | |
| SCHEMBL23928633 | 0.83 | NPSR1 (0.62) | LMNANPSR1ALDH1A1MAPTMEN1 | |
| SCHEMBL22095278 | 0.83 | LMNA (0.67) | LMNANPSR1ALDH1A1MAPTMEN1 | |
| SCHEMBL24711230 | 0.82 | MAPT (0.67) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2483606 | 0.82 | ALDH1A1 (0.69) | DCTPP1LMNANPSR1ALDH1A1MAPT | |
| SCHEMBL2388569 | 0.82 | MAPT (0.80) | LMNANPSR1ALDH1A1MAPTMEN1 | |
| SCHEMBL23928552 | 0.82 | LMNA (0.69) | LMNANPSR1ALDH1A1MAPTMEN1 | |
| SCHEMBL23928561 | 0.82 | NPSR1 (0.63) | LMNANPSR1ALDH1A1MAPTMEN1 | |
| SCHEMBL23928684 | 0.82 | LMNA (0.63) | LMNANPSR1ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9173886-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TRANA DISCOVERY, INC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TYMP, MAVS, ZC3HAV1 | DCTPP1 244/4885LMNA 2558/4885NPSR1 4662/4885 |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | DCTPP1 244/4885LMNA 2558/4885NPSR1 4662/4885 |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TYMP, MAVS, ZC3HAV1 | DCTPP1 244/4885LMNA 2558/4885NPSR1 4662/4885 |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | DCTPP1 244/4885LMNA 2558/4885NPSR1 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.